Interview with John Dawson, Founder & CEO, Alliance Pharma plc
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Address: Avonbridge House, Bath Road, Chippenham, Wiltshire SN15 2BB, United Kingdom ,United Kingdom
Tel: +44 (0)1249 466966
Web: http://www.camb-labs.com/default.asp
Alliance is a speciality pharmaceutical group based in the United Kingdom and listed on AIM. The group was founded in 1998 and since then has established a strong track record of acquiring the rights to established niche products. Alliance now owns or licences over 50 prescription products. Pro forma annual sales now exceed £40m.
Alliance maintains strategic and controlling functions with a management team possessing considerable large pharmaceutical company experience. More labour and capital intensive functions are outsourced to maximise efficiency and profitability.
The core of Alliances’ activities are in the United Kingdom and the Republic of Ireland. The group also sells into approximately 20 other countries Worldwide, including via a joint venture into China.
Anti Infective, Cough, Cold & Flu
Cardiovascular
Central Nervous System
Dental
Dermatology
Diagnostics
Nutrition
Obstetrics & Gynaecology
Rheumatology
Toxicology
Oncology
Endocrinology
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by…
Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and…
Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as…
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
Stewart Pearce, managing director of Otsuka UK and Ireland since 2017 discloses how he built up a leadership team fit for the Otsuka of 2023 and highlights what he appreciates…
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug…
Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how…
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Recently appointed CEO of Health Innovation Manchester, Ben Bridgewater explains the organization’s goal of improving the lives of the people of Greater Manchester by ensuring a constant pipeline of innovation,…
Taking the conversation beyond Brexit, His Excellency Lars Thuesen, ambassador of Denmark to the UK, highlights the solid ties that have linked both countries since the Danes invaded the island…
The Ambassador of Switzerland to the UK, Alexandre Fasel, discloses what has been achieved so far with the ‘Mind the Gap’ strategy, aimed at safeguarding British-Swiss economic and business…
See our Cookie Privacy Policy Here
